XTL Biopharmaceuticals
XTLB
3 hedge funds and large institutions have $293K invested in XTL Biopharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
8% more capital invested
Capital invested by funds: $271K → $293K (+$22.1K)
0% more funds holding
Funds holding: 3 → 3 (0)
0.01% less ownership
Funds ownership: 0.02% → 0.01% (-0.01%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$372 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$2.85K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NI
1
Noked Israel
Ramat Hasharon,
Israel
| $241K | – | – | – |
|
|
2
Morgan Stanley
New York
| $52K | -$2.85K | -575 | -5% |
|
|
3
UBS Group
Zurich,
Switzerland
| $363 | +$372 | +75 | New |
|
XTLB Hedge Fund Activity: Q4 2022 in Review
3 of the 6,224 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q4 2022, worth a combined $293K — up 8.2% from $271K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new XTLB positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $372. The largest seller was Morgan Stanley, cutting an estimated $2.85K.
- 3 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $293K of XTL Biopharmaceuticals stock for Q4 2022, up 8.2% quarter-over-quarter.
- 1 fund opened new XTL Biopharmaceuticals positions in Q4 2022 and 0 closed out, a net change of +1 holder.
- The largest XTL Biopharmaceuticals buyer in Q4 2022 was UBS Group, an estimated $372 added.
- The largest XTL Biopharmaceuticals seller in Q4 2022 was Morgan Stanley, an estimated $2.85K sold.
Based on aggregated 13F filings for Q4 2022.